iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.
Basic Details
Issuer Blackrock
Fund NameiShares Nasdaq Biotechnology ETF
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:IBB
Inception Date2/5/2001
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason
WebN/A
PhoneN/A
Fund Focus
Asset ClassEquity
BenchmarkNASDAQ Biotechnology TR USD
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America
Fund Statistics
Assets Under Management$9.58 billion
Average Daily Volume$2.36 million
Discount/Premium-0.82%
ETF Expenses
Management Fee0.47%
Other Expenses0.00%
Total Expenses0.47%
Fee Waiver0.00%
Net Expenses0.47%
Administrator, Advisor and Custodian
AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Trustee
Lead Market MakerVirtu Financial
iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) Frequently Asked Questions
What is iShares Nasdaq Biotechnology ETF's stock symbol?
iShares Nasdaq Biotechnology ETF trades on the NASDAQ under the ticker symbol "IBB."
How often does iShares Nasdaq Biotechnology ETF pay dividends? What is the dividend yield for iShares Nasdaq Biotechnology ETF?
iShares Nasdaq Biotechnology ETF declared a quarterly dividend on Tuesday, June 26th. Investors of record on Wednesday, June 27th will be paid a dividend of $0.1561 per share on Monday, July 2nd. This represents a $0.62 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date is Tuesday, June 26th. This is an increase from iShares Nasdaq Biotechnology ETF's previous quarterly dividend of $0.13. View iShares Nasdaq Biotechnology ETF's Dividend History.
When did iShares Nasdaq Biotechnology ETF's stock split? How did iShares Nasdaq Biotechnology ETF's stock split work?
iShares Nasdaq Biotechnology ETF shares split before market open on Friday, December 1st 2017. The 3-1 split was announced on Tuesday, November 7th 2017. The newly created shares were issued to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of iShares Nasdaq Biotechnology ETF stock prior to the split would have 300 shares after the split.
Are investors shorting iShares Nasdaq Biotechnology ETF?
iShares Nasdaq Biotechnology ETF saw a drop in short interest during the month of July. As of July 31st, there was short interest totalling 9,888,436 shares, a drop of 21.5% from the July 13th total of 12,603,071 shares. Based on an average trading volume of 2,658,090 shares, the short-interest ratio is currently 3.7 days. View iShares Nasdaq Biotechnology ETF's Current Options Chain.
Who are some of iShares Nasdaq Biotechnology ETF's key competitors?
Some companies that are related to iShares Nasdaq Biotechnology ETF include DNP Select Income Fund Inc. Common Stock (DNP), Nuveen Municipal Value Fund (NUV), Adams Diversified Equity Fund (ADX), Gabelli Equity Trust (GAB), Tortoise Energy Infrastructure (TYG), Tri-Continental (TY), PIMCO Corporate&Income Opportunity Fund (PTY), Royce Value Trust (RVT), Hercules Capital (HTGC), Liberty All-Star Equity Fund common stock (USA), Apollo Investment (AINV), Boulder Growth & Income Fund Inc common stock (BIF), PIMCO High Income Fund (PHK), AllianceBernstein Global Hgh Incm Fd (AWF) and Tekla Healthcare Investors (HQH).
Who are iShares Nasdaq Biotechnology ETF's key executives?
iShares Nasdaq Biotechnology ETF's management team includes the folowing people:
- George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees
- Michael Arthur Latham, President, Trustee
- Jack Gee, Chief Financial Officer, Treasurer
- Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
- , Bio & Compensation -
- Amy Schioldager, Executive Vice President
- Ira P. Shapiro, Vice President, Chief Legal Officer
- Matt Tucker, Vice President
- , Bio & Compensation -
- Eilleen M. Clavere, Secretary
- Cecilia H. Herbert, Independent Trustee
- Charles A. Hurty, Independent Trustee
Has iShares Nasdaq Biotechnology ETF been receiving favorable news coverage?
Media headlines about IBB stock have trended somewhat positive on Friday, according to Accern. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. iShares Nasdaq Biotechnology ETF earned a coverage optimism score of 0.00 on Accern's scale. They also gave news coverage about the financial services provider an impact score of 46.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for iShares Nasdaq Biotechnology ETF.
Who are iShares Nasdaq Biotechnology ETF's major shareholders?
iShares Nasdaq Biotechnology ETF's stock is owned by a number of of retail and institutional investors. Top institutional investors include Morgan Stanley (4.92%), Natixis (1.58%), Wells Fargo & Company MN (0.98%), PNC Financial Services Group Inc. (0.81%), Commerzbank Aktiengesellschaft FI (0.74%) and Main Management LLC (0.56%).
Which major investors are selling iShares Nasdaq Biotechnology ETF stock?
IBB stock was sold by a variety of institutional investors in the last quarter, including Synovus Financial Corp, First Republic Investment Management Inc., Ardsley Advisory Partners, Raymond James & Associates, Morgan Stanley, NF Trinity Capital Hong Kong Ltd, Belpointe Asset Management LLC and IFP Advisors Inc.
Which major investors are buying iShares Nasdaq Biotechnology ETF stock?
IBB stock was acquired by a variety of institutional investors in the last quarter, including Paloma Partners Management Co, Commerzbank Aktiengesellschaft FI, Raymond James Financial Services Advisors Inc., Cornerstone Wealth Management LLC, Natixis, SG Americas Securities LLC, Mader & Shannon Wealth Management Inc. and Investment Management of Virginia LLC.
How do I buy shares of iShares Nasdaq Biotechnology ETF?
Shares of IBB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is iShares Nasdaq Biotechnology ETF's stock price today?
One share of IBB stock can currently be purchased for approximately $116.27.
How big of a company is iShares Nasdaq Biotechnology ETF?
iShares Nasdaq Biotechnology ETF has a market capitalization of $9.22 billion.
MarketBeat Community Rating for iShares Nasdaq Biotechnology ETF (NASDAQ IBB)
MarketBeat's community ratings are surveys of what our community members think about iShares Nasdaq Biotechnology ETF and other stocks. Vote "Outperform" if you believe IBB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBB will underperform the S&P 500 over the long term. You may vote once every thirty days.
